Related Experiment Video

Updated: Dec 31, 2025

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.3K

Challenges of moving theranostic nanomedicine into the clinic

Deepika Singh1, Fahima Dilnawaz1, Sanjeeb Kumar Sahoo1

  • 1Nanomedicine Laboratory, Institute of Life Sciences, Nalco Square, Bhubaneswar, Odisha, 751023, India.

Nanomedicine (London, England)
|January 7, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
diagnosisdrug deliveryimagingnanomedicineregulatory governancetheranostic

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

687
Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
08:09

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

12.1K

Related Experiment Videos

Last Updated: Dec 31, 2025

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.3K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

687
Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
08:09

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

12.1K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K

Articles linked to this work by shared authors, journal, and citation graph.

SterilShield: Mechanically Robust, Fluorine-Free SiO2-CuO Nanocomposite Coatings with Combined Superhydrophobicity, Optical Transparency, and Antimicrobial Activity.

Langmuir : the ACS journal of surfaces and colloids·2026

Computational Predictions and Evolutionary Analysis of LrK10 Kinase-Related Putative PSTOL1 Gene Homeologs in Wheat and Orthologs of Its Wild Relatives.

International journal of molecular sciences·2026

Assessing Blood Pressure, Mental Health, and HRV Responses to Integrated Acupuncture in Hypertensive Patients: A Pilot Randomized Controlled Trial.

Medical acupuncture·2026

Genetic testing guides therapy in children with refractory cytopenias.

Haematologica·2026

PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation.

The Journal of clinical investigation·2025

Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity.

Cancer research·2025

mRNA-based nanomedicine for diabetic wound repair: advances in LNP delivery, immune modulation, and regenerative pathways.

Nanomedicine (London, England)·2026

Evolving skin cancer therapeutics: molecular and genetic drivers, immunotherapy challenges, and advances in nanogel-based nanomedicine.

Nanomedicine (London, England)·2026

Cardiac nanomedicine for ischemic injury and remodeling: imaging and therapy.

Nanomedicine (London, England)·2026

New approach methodologies to model the female reproductive tract: advances and opportunities for nanomedicine.

Nanomedicine (London, England)·2026

Heat-preconditioned MSC-derived exosomal miR‑486‑5p reverses doxorubicin resistance in breast cancer.

Nanomedicine (London, England)·2026

Dendrimer 'protein corona': mechanism of interaction, characterization, and implications in drug delivery.

Nanomedicine (London, England)·2026

Research progress in synergistic multimechanism of nanomaterial-mediated neuroinflammatory therapy (Review).

Molecular medicine reports·2026

Silver sodium nitroprusside nano-aggregates for ultrasound-activated immunomodulatory therapy of MRSA pneumonia.

Biomedical materials (Bristol, England)·2026

Neuro-psycho MMSig: multimodal mechanism enrichment platform for neuropsychiatric disorders.

Frontiers in bioinformatics·2026

Portable Ultra-Low-Field MRI in Neurologic Diseases: Current Status and Potential in Clinical Practice, Research, and Trials.

Neurology·2026

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry.

Leukemia·2026

Ultrasound-Enhanced Transport of Nanoparticles Through Extracellular Matrix-Acoustic Streaming and Diffusion.

Ultrasound in medicine & biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us